The U.S.Food and Drug Administration today approved Lonsurf(a pill that combines two drugs,trifluridine and tipiracil)for patients with an advanced form of colorectal cancer who are no longer responding to other therapies.'The past decade has brought a new understanding around colorectal cancer,in...
"Our novel prostate cancer drug works by a unique mechanism of action," said study lead author Jeremy Jones, PhD, assistant professor ofmolecular pharmacologyat City of Hope, Beckman Research Institute, in Duarte, CA. "Thus, it has the potential to treat cancers resistant to currently approved ...
People that have had dental work often remember having lidocaine for that. It's something that we use all the time, but we rarely think of it in terms of a cancer benefit; we just start doing it to prevent pain. To be able to use a commonly used medication, a drug that has great ...
The study, published inScience Advances, used amouse modelthat mimics human NASH-driven HCC to implement a combination treatment of an endoplasmic reticulum (ER) stress inhibitor called "BGP-15" with the inflammation blocker, "Olamkicept." Both of these drugs are already proven to be safe in ...
A week after the diagnosis, El-Afandi underwent surgery to remove the tumor. This is standard for glioblastoma treatment, but even after surgery, there's usually cancerous cells left behind because of the way the tumors grow in the brain. That's part of why the mortality rate for glioblasto...
for the first-line treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer. If you are trying to access a medication for colon cancer that is approved outside of your country of residence, we might be ...
as described in the Medication Guide. Patients treated with Enhertu may be at increased risk of developing left ventricular dysfunction, which occurs when the heart is unable to pump blood effectively to the body, as this has been seen with other HER2-directed therapies for ...
来源期刊 Emerging Infectious Diseases 研究点推荐 colon cancer 0关于我们 百度学术集成海量学术资源,融合人工智能、深度学习、大数据分析等技术,为科研工作者提供全面快捷的学术服务。在这里我们保持学习的态度,不忘初心,砥砺前行。了解更多>> 友情链接 联系我们 ...
Lorenzi, now at Janssen, and his team havea goal: determine the investigational medication’s safety and efficacy as a cancer treatment in patients with the gene-driven disease. In July, Janssen begins itsPhase 1 clinical trialsto determine just that, as well as the appropriate dosage for the...
Seventy percent of the patients who tested the medicine were stable after six weeks. Twelve continued the medication and were stable for 18 weeks. One woman took the medication for 17 months, and was stable for over two years. In other words, thecancerstopped growing. ...